Neurofenix, the neurological rehabilitation platform that uses sensor technology to improve patient recovery outcomes, has raised $7 million in Series A funding. This funding was led by AlbionVC, with additional participation by HTH, InHealth Ventures, and existing investors.  This will enable Neurofenix to build out its product line and invest in US expansion, including funding US clinical trials.

Founded in 2016 by Imperial graduates and Entrepreneur First alumni Guillem Singla Buxarrais (CEO) and Dimitrios Athanasiou (CTO), Neurofenix aims to revolutionise how neurological rehabilitation is delivered to drive better outcomes and recovery for patients.

“Neurofenix is poised to revolutionize physical recovery after a neurological injury, such as a stroke, traumatic brain injury or spinal cord injury. Its digital therapeutics platform, which can be used in rehabilitation clinics and by an individual bringing clinical-grade treatment into the home, which generates recovery of movement, strength, and activities of daily living faster and with better results. With my background as a neurosurgeon, I could see that Neurofenix is positioned to fill a major gap in the neuro-rehab industry.”

Read the full article: